1-(5-Chloro-2,3-dihydroxyphenyl)ethanone | 1154415-70-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(5-Chloro-2,3-dihydroxyphenyl)ethanone
• CAS: 1154415-70-9
• 化学式: C₈H₇ClO₃
• 分子量: 186.595
• InChiKey: WSWUMNZAZBLMNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-氯-2-甲氧基苯酚 、 溶剂黄146 在 三氟化硼 、 水 作用下， 反应 24.0h， 生成 1-(5-Chloro-2-hydroxy-3-methoxyphenyl)ethan-1-one 、 1-(5-Chloro-2,3-dihydroxyphenyl)ethanone
  参考文献：
  名称：

  [EN] EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS
  [FR] INHIBITEURS DU TRANSPORTEUR ÉQUILIBRANT DES NUCLÉOSIDES ENT1

  摘要：

  公开号：

  WO2009062990A3

文献信息

• EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS
  申请人：Bosmans Jean-Paul R.M.A.

  公开号：US20100280025A1

  公开（公告）日：2010-11-04

  The present invention is related to novel compounds of formula (I) having equilibrative nucleoside transporter ENT1 inhibiting properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the inhibition of ENT1 receptors in animals, in particular humans.
• SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF
  申请人：Memorial Sloan-Kettering Cancer Center

  公开号：US20220162209A1

  公开（公告）日：2022-05-26

  Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts or tautomers thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment and/or prevention of an infectious disease (e.g., bacterial infection (e.g., Mycobacterium infection (e.g., tuberculosis)). (I)
• US8263592B2
  申请人：——

  公开号：US8263592B2

  公开（公告）日：2012-09-11
• [EN] SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF<br/>[FR] ANALOGUES DE SALICYL-ADÉNOSINEMONOSULFAMATE ET LEURS UTILISATIONS
  申请人：MEMORIAL SLOAN KETTERING CANCER CENTER

  公开号：WO2020132603A2

  公开（公告）日：2020-06-25

  Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts or tautomers thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment and/or prevention of an infectious disease (e.g., bacterial infection (e.g., Mycobacterium infection (e.g., tuberculosis)). (I)
• [EN] EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS<br/>[FR] INHIBITEURS DU TRANSPORTEUR ÉQUILIBRANT DES NUCLÉOSIDES ENT1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009062990A3

  公开（公告）日：2009-09-24